Guardant Health
At the AACR annual meeting, both companies shared new data on their technologies' performance in detecting early and late-stage cancers.
Illumina Sues Guardant Health Over Patents, Trade Secrets, Breach of Contract
Illumina alleges that Guardant's founders misappropriated Illumina's confidential information and filed patent applications for their liquid biopsy startup based on Illumina's intellectual property.
Guardant Health Gets Japanese Approval for Tumor Mutation Profiling Liquid Biopsy Test
The test was also approved as a companion diagnostic for use with cancer drugs from Merck and Bristol Myers Squibb.
Guardant Health Begins SHIELD Trial for Lung Cancer Early Detection
The company will enroll 10,000 high-risk patients in the trial and evaluate the ability of its SHIELD blood test to detect lung cancer early.
JP Morgan Healthcare Conference Day 1: Novartis, Gilead, Johnson & Johnson, EQRx, Mirati, and More
Companies provided updates on precision oncology programs for CAR T-cell and biomarker-targeted therapies and announced plans for diagnostic and predictive tests.